Trials / Completed
CompletedNCT04336410
Safety, Tolerability and Immunogenicity of INO-4800 for COVID-19 in Healthy Volunteers
Phase 1 Open-label Study to Evaluate the Safety, Tolerability and Immunogenicity of INO-4800, a Prophylactic Vaccine Against SARS-CoV-2, Administered Intradermally Followed by Electroporation in Healthy Volunteers
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 120 (actual)
- Sponsor
- Inovio Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
This is an open-label trial to evaluate the safety, tolerability and immunological profile of INO-4800 administered by intradermal (ID) injection followed by electroporation (EP) using CELLECTRA® 2000 device in healthy adult volunteers.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | INO-4800 | INO-4800 will be administered ID on Day 0, Week 4 and at the optional Booster Dose Visit. |
| DEVICE | CELLECTRA® 2000 | EP using the CELLECTRA® 2000 device will be administered following ID delivery of INO-4800 on Day 0, Week 4 and at the optional Booster Dose Visit. |
Timeline
- Start date
- 2020-04-03
- Primary completion
- 2022-02-10
- Completion
- 2022-02-10
- First posted
- 2020-04-07
- Last updated
- 2022-04-15
Locations
3 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
- FDA-regulated device study
Source: ClinicalTrials.gov record NCT04336410. Inclusion in this directory is not an endorsement.